Cell and gene therapies are treatments that work at the level of your DNA or your living cells rather than using conventional drugs that circulate through your bloodstream. Gene therapies deliver, silence, or edit genetic instructions inside your cells to fix or compensate for a faulty gene. Cell therapies use living cells, often harvested from a patient or a donor and sometimes genetically modified in a lab, to fight disease or regenerate damaged tissue. The two fields increasingly overlap, since many of today’s most successful cell therapies involve genetically engineering a patient’s own immune cells before infusing them back. What makes both categories so different from traditional medicine is that they aim to address the root cause of a disease rather than manage symptoms.
How Gene Therapy Delivers New Instructions
At its simplest, gene therapy means getting a working copy of a gene, or a tool that can fix a broken one, into the right cells in your body. The hard part is the delivery. Your cells do not just absorb loose DNA floating around. You need a vehicle, often called a vector, to carry the genetic cargo inside.
The most common vectors are modified viruses. Viruses evolved over millions of years to be extremely good at inserting genetic material into human cells, so researchers strip out the disease-causing parts and load them with therapeutic genes instead. Adeno-associated viruses (AAVs) are among the most widely used because they can infect both dividing and non-dividing cells and produce long-lasting gene expression without integrating heavily into the host genome.1PubMed Central. Gene therapy using adeno-associated virus vectors Lentiviruses, derived from the same family as HIV but rendered harmless, are another workhorse, particularly for blood-cell therapies where you need the new gene to become a permanent part of the cell’s DNA.
Viruses are effective, but they come with baggage. They can trigger immune responses, they are expensive to manufacture at scale, and some people already carry antibodies against them. Roughly 30 to 60 percent of individuals have pre-existing antibodies against AAV, which can neutralize the vector before it ever reaches its target.2PubMed Central. Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy That has pushed researchers to develop non-viral alternatives. Lipid nanoparticles, the same basic technology behind some mRNA vaccines, can wrap genetic material in a fatty shell and shuttle it into cells. Polymer-based particles, inorganic nanoparticles, and even tiny natural vesicles shed by cells are also being explored as delivery systems.3PubMed Central. Emerging non-viral vectors for gene delivery None of these non-viral approaches match viral vectors in efficiency yet, but they are catching up fast, particularly for delivering gene-editing tools like CRISPR.4PubMed Central. Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
In Vivo Versus Ex Vivo
There are two broad strategies for getting a therapy into the right cells, and the choice depends largely on which organ or tissue you need to reach. In vivo therapy means injecting the vector directly into the patient’s body and letting it find its target cells on its own. This is the approach used when the goal is to reach cells inside organs like the liver, eye, or nervous system that you cannot easily remove, modify, and return. Ex vivo therapy means taking cells out of the patient, modifying them in a lab, and infusing the engineered cells back in. This approach is most common for blood cells and immune cells, which are relatively easy to collect and culture outside the body.5PubMed. The Future of Gene Therapy: A Review of In Vivo and Ex Vivo Delivery Methods for Genome Editing-Based Therapies
The ex vivo route has a practical advantage: you can check the modified cells for accuracy and safety before they go back into the patient. The in vivo route is simpler from the patient’s perspective, often requiring just a single injection, but controlling exactly which cells take up the vector and how much gene product they make is harder.
Gene Editing and CRISPR
Traditional gene therapy adds a new, functional copy of a gene without necessarily fixing the original broken one. Gene editing goes further. It changes the patient’s own DNA at a precise location, correcting a mutation, disabling a harmful gene, or inserting new sequence where it is needed. CRISPR-Cas9 is the most well-known tool for this. It works by guiding an enzyme (Cas9) to a specific spot in the genome using a short RNA sequence that matches the target. Once there, Cas9 cuts both strands of the DNA. The cell’s own repair machinery then patches things up, and researchers can influence how that repair happens to achieve the desired result.6PubMed Central. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
One repair pathway tends to produce small insertions or deletions at the cut site, which is useful when the goal is simply to disable a gene. Another pathway can incorporate a provided DNA template to make a precise correction, though this process is less efficient. Recent engineering of the Cas9 enzyme itself has improved the balance, producing variants that suppress the imprecise repair pathway and favor precise corrections in both dividing and non-dividing cells.7PubMed Central. Altered DNA repair pathway engagement by engineered CRISPR-Cas9 nucleases
Even more refined tools have emerged. Base editors can swap one DNA letter for another without cutting both strands of the double helix at all, reducing the risk of unwanted changes. Prime editors extend this further, handling all twelve possible single-letter swaps as well as small insertions and deletions.8PubMed Central. CRISPR-Cas9 DNA Base-Editing and Prime-Editing Think of standard CRISPR as cutting a page out of a book and taping in a new one, base editing as using correction fluid on a single letter, and prime editing as a precise search-and-replace function. Each tool suits different kinds of genetic errors.
How CAR-T Cell Therapy Works
The most prominent cell therapy today is CAR-T (chimeric antigen receptor T-cell) therapy. The basic idea is to take a patient’s own T cells, a type of immune cell, and genetically engineer them to recognize and attack cancer. A synthetic gene is inserted into the T cells that encodes a custom receptor on their surface. This receptor has an external portion that locks onto a specific protein found on tumor cells and an internal portion that sends a strong activation signal to the T cell once it binds its target.
Early designs of CARs had only the basic activation signal and performed poorly in patients. Researchers discovered that adding a co-stimulatory signal was essential for the T cells to expand, persist, and actually kill tumors effectively.9PubMed Central. Co-Stimulatory Receptor Signaling in CAR-T Cells Today, all CAR-T therapies in clinical use include at least one co-stimulatory domain. The two most common are CD28 and 4-1BB, and they produce different behavior. CD28-containing CARs tend to expand faster and hit harder in the short term, while 4-1BB-containing CARs persist longer and may produce a more durable response. The choice between them can influence the safety profile and how well the therapy works over time.10PubMed Central. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Beyond CAR-T: Stem Cells and Regenerative Therapies
Cell therapy extends well beyond cancer immunotherapy. Mesenchymal stem cells (MSCs) are used in regenerative medicine because they can differentiate into various tissue types and have natural anti-inflammatory and immune-modulating properties. They are also relatively low-risk in terms of triggering immune rejection, which means donor-derived MSCs can sometimes be used without needing a match from the patient’s own body.11PubMed Central. MSCs vs. iPSCs: Potential in therapeutic applications
Induced pluripotent stem cells (iPSCs) represent another avenue. These are ordinary adult cells that have been reprogrammed back to a stem-cell-like state, meaning they can theoretically become almost any cell type in the body. Researchers are exploring iPSC-derived MSCs as a way to combine the versatility of iPSCs with the therapeutic properties of MSCs. Interestingly, iPSC-derived MSCs appear to have stronger immunosuppressive signaling than MSCs taken directly from umbilical cord tissue, and they may be better at differentiating into neural cell types, potentially opening doors for neurological applications.12Heliyon. Comparative analysis of mesenchymal stem/stromal cells derived from human induced pluripotent stem cells and the cognate umbilical cord mesenchymal stem/stromal cells
Where These Therapies Are Already Working
The most dramatic clinical success stories come from blood cancers and genetic blood disorders. CAR-T cells targeting the CD19 protein on B cells have produced striking remission rates in patients with B-cell malignancies who had exhausted conventional treatments.13Blood. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date Several products targeting CD19 are now approved for conditions like certain types of lymphoma and acute lymphoblastic leukemia.
For genetic diseases, gene therapy for spinal muscular atrophy (SMA) stands out. SMA is caused by a missing or defective gene (SMN1) that leads to progressive muscle wasting. In a landmark trial, infants with the most severe form of SMA received a single intravenous dose of an AAV9 vector carrying a functional copy of the SMN gene. These children survived longer, achieved motor milestones like sitting and head control, and showed better motor function compared to what the disease would have otherwise allowed.14PubMed. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy Research continues into second-generation vectors with optimized versions of the gene that may improve long-term outcomes.15Nature Communications. Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice
Sickle cell disease offers one of the clearest demonstrations of CRISPR’s clinical potential. The disease is caused by a single mutation in the hemoglobin gene that distorts red blood cells into a rigid, sickle shape. Rather than directly fixing that mutation, researchers found an elegant workaround. Everyone is born producing fetal hemoglobin, which does not sickle, but a gene called BCL11A switches off fetal hemoglobin production after birth. By using CRISPR to disable the BCL11A gene in a patient’s own blood stem cells, researchers reawakened fetal hemoglobin production. In early patients, more than a year after treatment, edited cells were thriving in the bone marrow, fetal hemoglobin levels were high, and the patient with sickle cell disease was free of the painful vaso-occlusive episodes that define the condition.16PubMed Central. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease These results led to the first CRISPR-based therapy to receive regulatory approval.
Safety Risks and Side Effects
For all their promise, these therapies carry real risks. CAR-T therapy can trigger cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that occurs when the engineered T cells activate massively and dump immune signaling molecules into the bloodstream. Symptoms range from fever and low blood pressure to organ damage. Neurological toxicity is another recognized side effect. While these complications are manageable in most cases with supportive care and specific drugs, they can be serious enough to require intensive-care admission, and deaths have occurred.17PubMed Central. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden
Gene therapies using viral vectors carry the risk of the vector inserting into the wrong part of the genome. In early gene therapy trials using a different type of virus (retroviruses), this insertion occasionally landed near genes that control cell growth, effectively switching on a cancer-promoting gene and causing leukemia in some patients.18PubMed Central. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity Modern vectors are designed to minimize this risk, but it has not been eliminated entirely.
CRISPR-based therapies face the concern of off-target editing: cuts or changes made at unintended locations in the genome that could disrupt important genes or create new problems.19PubMed Central. Off-target effects in CRISPR/Cas9 gene editing Clinical results so far have been reassuring on this front, with studies reporting no detectable off-target mutations in treated patients, but long-term surveillance is still in its early days. The sickle cell trials, for instance, reported roughly 80 percent editing at the intended site with no evidence of off-target changes.20PubMed. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Why Solid Tumors Remain Difficult
CAR-T therapy has been transformative for blood cancers, but extending that success to solid tumors like lung, breast, or colon cancer has proven far harder. Blood cancers conveniently express surface markers, like CD19, that are relatively specific and accessible. Solid tumors present a different set of problems. They often lack a single, unique surface target that cleanly distinguishes cancer cells from healthy tissue. The tumor creates a hostile local environment that suppresses immune cell activity. And T cells struggle to physically infiltrate the dense, fibrous architecture of many solid tumors.21PubMed Central. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors Tumor heterogeneity compounds the problem: even within a single tumor, different cells can express different surface proteins, meaning a CAR designed against one target may miss a large fraction of the cancer.22PubMed Central. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment Researchers are testing multi-target CARs, armored CARs that secrete immune-stimulating molecules into the tumor, and combination approaches, but reliable results in solid tumors remain an unmet goal.
Manufacturing Complexity and Cost
Making these therapies is nothing like producing a pill in a factory. For autologous CAR-T therapy, each treatment is a bespoke product manufactured from a single patient’s cells. The cells must be collected, shipped to a specialized facility, genetically modified, expanded to large numbers, quality-tested, and shipped back, often under strict temperature-controlled conditions. Donor-to-donor biological variability, contamination risks during processing, and cold-chain instability all threaten the final product’s quality and consistency.23PubMed. Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective
Viral vector production faces its own bottlenecks. Scaling up AAV or lentiviral production requires large amounts of genetic material and transfection reagents, driving up costs and introducing batch-to-batch variability. Purification is a major hurdle: separating full, functional viral particles from empty capsids (virus shells that contain no therapeutic gene) is technically demanding, and leftover empty capsids can provoke unwanted immune reactions in patients.24Annals of Laboratory Medicine. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation
These manufacturing realities explain much of the sticker shock. Approved gene therapies for conditions like SMA or inherited retinal disease carry price tags in the hundreds of thousands to millions of dollars per patient. The manufacturing infrastructure required is expensive to build, operate, and validate, and the per-patient nature of autologous therapies means economies of scale are hard to achieve.25PubMed Central. Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India Allogeneic approaches, which use donor-derived or off-the-shelf cells rather than each patient’s own, are being developed partly to bring costs down and make therapy accessible to a broader patient population.
In Vivo CAR-T and the Push to Skip the Lab
Perhaps the most exciting frontier is the idea of engineering a patient’s immune cells directly inside their body, eliminating the weeks-long ex vivo manufacturing process entirely. Several research groups are developing targeted lipid nanoparticles that can deliver CAR-encoding mRNA specifically to T cells circulating in the bloodstream. In one approach, nanoparticles coated with antibodies that bind T cells successfully reprogrammed CD8+ T cells in both lab samples and living animals, producing tumor control in mice and B cell depletion in monkeys.26PubMed. In vivo CAR T cell generation to treat cancer and autoimmune disease Another group achieved antibody-dependent and dose-dependent CAR expression in vivo, with B cell depletion of up to 90 percent in animal models.27PubMed. In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
Because mRNA is inherently temporary and degrades within days, in vivo CAR-T would produce transient rather than permanent CAR expression. That is actually a feature for some applications: it means the therapy could be dosed repeatedly and dialed up or down, more like a conventional drug than a one-shot permanent modification. It could also make CAR-T therapy relevant for autoimmune diseases, where you want to briefly deplete a problematic immune cell population without wiping it out forever. If these approaches translate from animal models to human patients, they could collapse the cost and logistical complexity of CAR-T therapy dramatically, turning what is currently a specialty treatment at a handful of medical centers into something that could be administered at a typical hospital infusion clinic.
Why Accessibility Remains Unequal
Even where cell and gene therapies are approved and available, access is profoundly unequal. The cost barrier alone restricts treatment to wealthy countries with sophisticated healthcare reimbursement systems. Manufacturing facilities are concentrated in North America and Europe, and the cold-chain logistics needed to ship living cells or viral vectors limit practical reach. Regulatory frameworks in low- and middle-income countries are still developing, creating additional delays between approval in one market and availability in another.25PubMed Central. Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India For diseases like sickle cell, which disproportionately affects populations in sub-Saharan Africa and South Asia, the irony is sharp: the people who stand to benefit most from a cure are the least likely to receive one under current conditions. Solving this will require not just cheaper manufacturing but distributed production capacity, adapted regulatory pathways, and creative payment models that can spread a one-time curative therapy’s cost over many years.